Revenue segments as reported by the company.

Net product sales

Alliance and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Marketing, selling and administrative

Research and development

IPRD charge - MyoKardia acquisition

Amortization of acquired intangible assets

Other (income)/ expense, net

Acquired IPRD

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bristol-Myers

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bristol-Myers reports robust 2022 performance and outlines growth strategies

Bristol-Myers Squibb delivered strong financial performance in 2022, with revenue growth and key product successes driving sales to $46 billion.
The company's strategic focus on portfolio expansion, market access enhancement, and operational efficiency positions it for continued growth and value creation.
Challenges around market access, legislative impacts, and expense management require strategic attention, while opportunities in product development and market expansion offer avenues for future growth.

Bristol-Myers reports robust Q1 earnings, eyes growth amid challenges

Bristol-Myers' Q1 2023 performance reflects strong sales growth and a focus on innovation, with significant progress in pipeline development and new product launches.
While facing challenges from generic competition and operational issues, the company is well-positioned to capitalize on industry advancements and strategic opportunities for growth.
By reaffirming guidance, emphasizing strategic alignment, and pursuing new therapies, Bristol-Myers demonstrates resilience and a commitment to long-term success in the pharmaceutical market.

Bristol-Myers reports robust Q2 sales and strategic growth initiatives

Bristol-Myers' Q2 performance showcased strong sales driven by new product growth and key product successes like Opdivo and Reblozyl.
While facing challenges with certain products and revenue guidance changes, the company remains confident in its financial commitments and growth outlook.
Opportunities lie in capacity ramp-up for key products, conversion strategies for patient assistance programs, and upcoming R&D insights.
Overall, Bristol-Myers' performance, strengths, and opportunities position the company for continued growth and success in the pharmaceutical market.

Bristol-Myers reports robust Q3 performance, eyes growth opportunities

Bristol-Myers Squibb's Q3 earnings call highlighted strong performance, strategic initiatives for growth, and confidence in future prospects. Despite challenges in product performance and reimbursement, the company is optimistic about market improvements and growth opportunities. Executives are focused on driving sustainable long-term growth and expanding their product portfolio.

Bristol-Myers reports robust Q4 earnings, eyes growth through strategic initiatives

Bristol-Myers' Q4 2023 showcased strong financial performance, strategic advancements, and a focus on growth drivers like Opdivo and new launches.
Despite challenges in negotiations and market dynamics, Bristol-Myers remains poised for growth through its robust product portfolio and business development strategies.
The company's emphasis on innovation, commercial execution, and clinical progress positions Bristol-Myers for sustained growth and market leadership in the pharmaceutical industry.

Bristol-Myers meets Q1 expectations, focuses on growth opportunities

Bristol-Myers Squibb's Q1 performance met expectations with strong sales growth driven by key brands and strategic acquisitions.
Despite challenges in operating expenses and interest costs impacting income, the focus on efficiency and cost savings remains a priority.
The company's strengths lie in robust sales growth of key brands, promising pipeline advancements, and strategic capital allocation plans.
Opportunities in expanding indications, new trials, and market launches position Bristol-Myers for long-term growth and competitive advantage.

Bristol-Myers reports strong Q2 performance, bullish on pipeline growth

Bristol-Myers (BMY) showcased a robust Q2 performance, emphasizing pipeline advancements and strategic capital allocation for growth and returns.
The company is confident in navigating pricing changes and improving access dynamics for key products, while focusing on transformative medicines and operational excellence.
With a positive outlook for the year, Bristol-Myers is poised to leverage opportunities in oncology, pipeline advancements, and expanding indications for key assets.

Bristol-Myers (BMY) reports strong Q3 sales and pipeline progress

Bristol-Myers Squibb (BMY) showcased robust performance with strong sales growth and positive clinical data for pipeline programs.
The company's strategic strengths lie in operational excellence, capital allocation, and commitment to sustainable growth and innovation.
Challenges include market dynamics, competition in heart failure drugs, and translating clinical data into successful drug programs.
Opportunities abound in the growing heart failure drugs market, upcoming trial data readouts, and continued focus on portfolio growth and operational efficiency.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Pfizer

Which stock wins in a battle between these two big drugmakers?

Better Buy: Pfizer vs. Bristol Myers Squibb

Opdivo plus Yervoy has a chance to challenge Keytruda for a share of newly diagnosed lung cancer patients.

Bristol Myers Squibb's Cancer Combo Gets a Green Light from the FDA

Clorox

Target

These stocks -- a pharmaceutical company, a retailer, and a consumer staples name -- may keep your portfolio well-balanced during the next market crash.

3 Stocks to Buy Ahead  of the Next Market Crash

Bristol-Myers' (BMY) BLA seeking approval for CAR-T therapy candidate, idecabtagene vicleucel, for treating relapsed and refractory multiple myeloma gets FDA's refusal. The company plans to re-submit the BLA by July.

Bristol-Myers Gets Refusal to File Letter for CAR-T Therapy BLA

B&G Foods

Fortinet

Moderna

ServiceNow

NVIDIA

At this stage, a combination of aggressive and defensive stocks after filtering with proper selection criteria will be prudent for one's portfolio.

Rebalance Your Portfolio to Counter Dilemma Over Recovery

The FDA won't review a biologics license application for ide-cel until the company fills in some missing details.

Bristol Myers Squibb Receives a 'Refuse to File' Letter for an Experimental Cancer Therapy on a Deadline

AstraZeneca

Eli Lilly

Sanofi

Here we highlight five large drugmakers that can be added to one's portfolio amid the coronavirus crisis.

Drug Sector Highly Resilient Amid Coronavirus Mayhem: 5 Picks

Shares of Bluebird Bio Inc. BLUE, -5.59% declined 5.9% in premarket trading on Wednesday after the company and Bristol-Myers Squibb Co.

Bluebird, Bristol-Myers Squibb have resubmit FDA bid for CAR-T therapy

Painful setbacks with the FDA approval process of its newest oncology therapeutic point to deeper issues within the company.

Is Bristol Myers Squibb Losing Its Edge As A Growth Stock?

Bristol-Myers (BMY) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Bristol-Myers (BMY) is an Incredible Growth Stock: 3 Reasons Why

AbbVie

Cardinal Health

CVS Health

Walgreens

These five healthcare stocks have low P/E ratios and ample yields, making them cheap and profitable options for investors.

5 Healthcare Stocks That Are Profitable but Also Cheap

bluebird bio

The pharma giant and the smaller biotech will keep working together on a couple of promising CAR-T cancer therapies.

Bristol Myers Squibb Offers bluebird bio a $200 Million Royalty Buyout

Bristol-Myers Squibb: This Could Be The Next Quarter Trillion Dollar Company

Amgen

BioMarin Pharmaceutical

Vertex Pharmaceuticals

Biopharma shares have outperformed the broader market year-to-date, giving rise to apprehension over whether a pullback is in the offing.

5 Biopharmas Where BofA Would Put Its Money To Work

Pharmaceutical company Bristol Myers advanced in 2019 despite shareholder opposition to its Celgene buyout. Now that Bristol has officially acquired Celgene, is it time to buy BMY stock?

The No. 1 Pharma Stock Just Crushed Earnings Views — Is BMY Stock A Buy?

GlaxoSmithKline

Friday's big stock charts feature pharmaceutical-market names that recently posted terrific earnings data.
The post 3 Big Stock Charts for Friday: Bristol-Myers Squibb, Eli Lilly, and GlaxoSmithKline appeared first on InvestorPlace.

3 Big Stock Charts for Friday: Bristol-Myers Squibb, Eli Lilly, and GlaxoSmithKline

Bristol-Myers Squibb Company (BMY) CEO Giovanni Caforio on Q1 2020 Results - Earnings Call Transcript

Bristol-Myers (BMY) beats on earnings and sales in the first quarter on strong performance of Revlimid and Eliquis.

Bristol-Myers' (BMY) Q1 Earnings & Sales Beat Estimates

The big drugmaker's blockbuster cancer immunotherapy Opdivo wasn't one of them.

3 Reasons Bristol Myers Squibb's Revenue Skyrocketed in Q1

Gilead Sciences

Clovis Oncology

Merck

Despite a busy few months with emergency use authorizations due to coronavirus, the Food and Drug Administration is expected to approve several new drugs in May.

From Gilead To AstraZeneca, Investors Should Watch These Biotech Giants Right Now

Bristol-Myers (BMY) delivered earnings and revenue surprises of 16.22% and 8.62%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Bristol-Myers Squibb (BMY) Tops Q1 Earnings and Revenue Estimates

Bank of America

Banking, Buffett, and big pharma make for a super-attractive list of bargain stocks.

These 3 Value Stocks  Are Absurdly Cheap Right Now

Shares of Bristol-Myers Squibb BMY, -0.37% gained 2.6% in premarket trading on Thursday after the drugmaker posted stronger-than-expected adjusted first-quarter earnings.

Bristol-Myers Squibb's stock gains 2% on strong EPS

Bristol Myers easily beat first-quarter earnings views. The drug giant also reaffirmed 2020 EPS guidance.

Bristol Myers Earnings Beat Views; Drug Giant Nears Buy Point

Celgene

The Food and Drug Administration moved its action date on  liso-cell back by three months.

News for Bristol-Myers Stock (BMY)